Loading…

The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC)

Renal cell cancer (RCC) has traditionally been considered radioresistant. Because of this, conventional radiotherapy (RT) has been predominantly relegated to the palliation of symptomatic metastatic disease. The implementation of stereotactic ablative radiotherapy (SABR) has made it possible to deli...

Full description

Saved in:

Bibliographic Details
Published in:	Cancers 2024-07, Vol.16 (15), p.2678
Main Authors:	Moreno-Olmedo, Elena, Sabharwal, Ami, Das, Prantik, Dallas, Nicola, Ford, Daniel, Perna, Carla, Camilleri, Philip
Format:	Article
Language:	English
Subjects:	Ablation Cancer therapies Clinical trials Cryotherapy Dialysis Hemodialysis Immunogenicity Invasiveness Kidney cancer Metastases Metastasis Oncology Palliation Patients Radiation therapy Radioresistance Radiosurgery Renal function Surgery Surgical outcomes Toxicity Tumors
Citations:	Items that this one cites
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by
cites	cdi_FETCH-LOGICAL-c209t-a41bee70ea2d496bcb9b68d970186165128bad023ccf996f8e409cd3c44188c23
container_end_page
container_issue	15
container_start_page	2678
container_title	Cancers
container_volume	16
creator	Moreno-Olmedo, Elena Sabharwal, Ami Das, Prantik Dallas, Nicola Ford, Daniel Perna, Carla Camilleri, Philip
description	Renal cell cancer (RCC) has traditionally been considered radioresistant. Because of this, conventional radiotherapy (RT) has been predominantly relegated to the palliation of symptomatic metastatic disease. The implementation of stereotactic ablative radiotherapy (SABR) has made it possible to deliver higher ablative doses safely, shifting the renal radioresistance paradigm. SABR has increasingly been adopted into the multidisciplinary framework for the treatment of locally recurrent, oligoprogressive, and oligometastatic disease. Furthermore, there is growing evidence of SABR as a non-invasive definitive therapy in patients with primary RCC who are medically inoperable or who decline surgery, unsuited to invasive ablation (surgery or percutaneous techniques), or at high-risk of requiring post-operative dialysis. Encouraging outcomes have even been reported in cases of solitary kidney or pre-existing chronic disease (poor eGFR), with a high likelihood of preserving renal function. A review of clinical evidence supporting the use of ablative radiotherapy (SABR) in primary, recurrent, and metastatic RCC has been conducted. Given the potential immunogenic effect of the high RT doses, we also explore emerging opportunities to combine SABR with systemic treatments. In addition, we explore future directions and ongoing clinical trials in the evolving landscape of this disease.
doi_str_mv	10.3390/cancers16152678
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3091284977</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3091284977</sourcerecordid><originalsourceid>FETCH-LOGICAL-c209t-a41bee70ea2d496bcb9b68d970186165128bad023ccf996f8e409cd3c44188c23</originalsourceid><addsrcrecordid>eNpdkM1Lw0AQxRdRrNSevcmCl_YQux_pZvdYg19QENLqNWw2E5qSZuNuIvS_N7ZVpHOYmcNvHm8eQjeU3HOuyNTo2oDzVNAZE5E8Q1eMRCwQQoXn__YBGnm_IX1xTiMRXaIBV5TxkIgr9LFaA17oOvdGN4BtgZctOLCtNm1p8DyrdFt-AU50Xtp2DU43Ozxezh-SCS6swwnUusIxVH3b28HjJI4n1-ii0JWH0XEO0fvT4yp-CRZvz6_xfBEYRlQb6JBmABEBzfJQicxkKhMyVxGhUlAxo0xmOieMG1MoJQoJIVEm5yYMqZSG8SEaH3QbZz878G26Lb3p3egabOdTTvpPZaiiqEfvTtCN7Vzvfk8RKbmSoqemB8o4672DIm1cudVul1KS_qSenqTeX9wedbtsC_kf_5sx_wbaVnt2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3090883986</pqid></control><display><type>article</type><title>The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC)</title><source>NCBI_PubMed Central（免费）</source><source>ProQuest - Publicly Available Content Database</source><creator>Moreno-Olmedo, Elena ; Sabharwal, Ami ; Das, Prantik ; Dallas, Nicola ; Ford, Daniel ; Perna, Carla ; Camilleri, Philip</creator><creatorcontrib>Moreno-Olmedo, Elena ; Sabharwal, Ami ; Das, Prantik ; Dallas, Nicola ; Ford, Daniel ; Perna, Carla ; Camilleri, Philip</creatorcontrib><description>Renal cell cancer (RCC) has traditionally been considered radioresistant. Because of this, conventional radiotherapy (RT) has been predominantly relegated to the palliation of symptomatic metastatic disease. The implementation of stereotactic ablative radiotherapy (SABR) has made it possible to deliver higher ablative doses safely, shifting the renal radioresistance paradigm. SABR has increasingly been adopted into the multidisciplinary framework for the treatment of locally recurrent, oligoprogressive, and oligometastatic disease. Furthermore, there is growing evidence of SABR as a non-invasive definitive therapy in patients with primary RCC who are medically inoperable or who decline surgery, unsuited to invasive ablation (surgery or percutaneous techniques), or at high-risk of requiring post-operative dialysis. Encouraging outcomes have even been reported in cases of solitary kidney or pre-existing chronic disease (poor eGFR), with a high likelihood of preserving renal function. A review of clinical evidence supporting the use of ablative radiotherapy (SABR) in primary, recurrent, and metastatic RCC has been conducted. Given the potential immunogenic effect of the high RT doses, we also explore emerging opportunities to combine SABR with systemic treatments. In addition, we explore future directions and ongoing clinical trials in the evolving landscape of this disease.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16152678</identifier><identifier>PMID: 39123406</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Ablation ; Cancer therapies ; Clinical trials ; Cryotherapy ; Dialysis ; Hemodialysis ; Immunogenicity ; Invasiveness ; Kidney cancer ; Metastases ; Metastasis ; Oncology ; Palliation ; Patients ; Radiation therapy ; Radioresistance ; Radiosurgery ; Renal function ; Surgery ; Surgical outcomes ; Toxicity ; Tumors</subject><ispartof>Cancers, 2024-07, Vol.16 (15), p.2678</ispartof><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c209t-a41bee70ea2d496bcb9b68d970186165128bad023ccf996f8e409cd3c44188c23</cites><orcidid>0000-0001-7508-1544 ; 0000-0002-2677-5627</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3090883986/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3090883986?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25751,27922,27923,37010,37011,44588,74896</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39123406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moreno-Olmedo, Elena</creatorcontrib><creatorcontrib>Sabharwal, Ami</creatorcontrib><creatorcontrib>Das, Prantik</creatorcontrib><creatorcontrib>Dallas, Nicola</creatorcontrib><creatorcontrib>Ford, Daniel</creatorcontrib><creatorcontrib>Perna, Carla</creatorcontrib><creatorcontrib>Camilleri, Philip</creatorcontrib><title>The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC)</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Renal cell cancer (RCC) has traditionally been considered radioresistant. Because of this, conventional radiotherapy (RT) has been predominantly relegated to the palliation of symptomatic metastatic disease. The implementation of stereotactic ablative radiotherapy (SABR) has made it possible to deliver higher ablative doses safely, shifting the renal radioresistance paradigm. SABR has increasingly been adopted into the multidisciplinary framework for the treatment of locally recurrent, oligoprogressive, and oligometastatic disease. Furthermore, there is growing evidence of SABR as a non-invasive definitive therapy in patients with primary RCC who are medically inoperable or who decline surgery, unsuited to invasive ablation (surgery or percutaneous techniques), or at high-risk of requiring post-operative dialysis. Encouraging outcomes have even been reported in cases of solitary kidney or pre-existing chronic disease (poor eGFR), with a high likelihood of preserving renal function. A review of clinical evidence supporting the use of ablative radiotherapy (SABR) in primary, recurrent, and metastatic RCC has been conducted. Given the potential immunogenic effect of the high RT doses, we also explore emerging opportunities to combine SABR with systemic treatments. In addition, we explore future directions and ongoing clinical trials in the evolving landscape of this disease.</description><subject>Ablation</subject><subject>Cancer therapies</subject><subject>Clinical trials</subject><subject>Cryotherapy</subject><subject>Dialysis</subject><subject>Hemodialysis</subject><subject>Immunogenicity</subject><subject>Invasiveness</subject><subject>Kidney cancer</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Palliation</subject><subject>Patients</subject><subject>Radiation therapy</subject><subject>Radioresistance</subject><subject>Radiosurgery</subject><subject>Renal function</subject><subject>Surgery</subject><subject>Surgical outcomes</subject><subject>Toxicity</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkM1Lw0AQxRdRrNSevcmCl_YQux_pZvdYg19QENLqNWw2E5qSZuNuIvS_N7ZVpHOYmcNvHm8eQjeU3HOuyNTo2oDzVNAZE5E8Q1eMRCwQQoXn__YBGnm_IX1xTiMRXaIBV5TxkIgr9LFaA17oOvdGN4BtgZctOLCtNm1p8DyrdFt-AU50Xtp2DU43Ozxezh-SCS6swwnUusIxVH3b28HjJI4n1-ii0JWH0XEO0fvT4yp-CRZvz6_xfBEYRlQb6JBmABEBzfJQicxkKhMyVxGhUlAxo0xmOieMG1MoJQoJIVEm5yYMqZSG8SEaH3QbZz878G26Lb3p3egabOdTTvpPZaiiqEfvTtCN7Vzvfk8RKbmSoqemB8o4672DIm1cudVul1KS_qSenqTeX9wedbtsC_kf_5sx_wbaVnt2</recordid><startdate>20240727</startdate><enddate>20240727</enddate><creator>Moreno-Olmedo, Elena</creator><creator>Sabharwal, Ami</creator><creator>Das, Prantik</creator><creator>Dallas, Nicola</creator><creator>Ford, Daniel</creator><creator>Perna, Carla</creator><creator>Camilleri, Philip</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7508-1544</orcidid><orcidid>https://orcid.org/0000-0002-2677-5627</orcidid></search><sort><creationdate>20240727</creationdate><title>The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC)</title><author>Moreno-Olmedo, Elena ; Sabharwal, Ami ; Das, Prantik ; Dallas, Nicola ; Ford, Daniel ; Perna, Carla ; Camilleri, Philip</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c209t-a41bee70ea2d496bcb9b68d970186165128bad023ccf996f8e409cd3c44188c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Ablation</topic><topic>Cancer therapies</topic><topic>Clinical trials</topic><topic>Cryotherapy</topic><topic>Dialysis</topic><topic>Hemodialysis</topic><topic>Immunogenicity</topic><topic>Invasiveness</topic><topic>Kidney cancer</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Palliation</topic><topic>Patients</topic><topic>Radiation therapy</topic><topic>Radioresistance</topic><topic>Radiosurgery</topic><topic>Renal function</topic><topic>Surgery</topic><topic>Surgical outcomes</topic><topic>Toxicity</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moreno-Olmedo, Elena</creatorcontrib><creatorcontrib>Sabharwal, Ami</creatorcontrib><creatorcontrib>Das, Prantik</creatorcontrib><creatorcontrib>Dallas, Nicola</creatorcontrib><creatorcontrib>Ford, Daniel</creatorcontrib><creatorcontrib>Perna, Carla</creatorcontrib><creatorcontrib>Camilleri, Philip</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Biological Sciences</collection><collection>ProQuest research library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moreno-Olmedo, Elena</au><au>Sabharwal, Ami</au><au>Das, Prantik</au><au>Dallas, Nicola</au><au>Ford, Daniel</au><au>Perna, Carla</au><au>Camilleri, Philip</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC)</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-07-27</date><risdate>2024</risdate><volume>16</volume><issue>15</issue><spage>2678</spage><pages>2678-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Renal cell cancer (RCC) has traditionally been considered radioresistant. Because of this, conventional radiotherapy (RT) has been predominantly relegated to the palliation of symptomatic metastatic disease. The implementation of stereotactic ablative radiotherapy (SABR) has made it possible to deliver higher ablative doses safely, shifting the renal radioresistance paradigm. SABR has increasingly been adopted into the multidisciplinary framework for the treatment of locally recurrent, oligoprogressive, and oligometastatic disease. Furthermore, there is growing evidence of SABR as a non-invasive definitive therapy in patients with primary RCC who are medically inoperable or who decline surgery, unsuited to invasive ablation (surgery or percutaneous techniques), or at high-risk of requiring post-operative dialysis. Encouraging outcomes have even been reported in cases of solitary kidney or pre-existing chronic disease (poor eGFR), with a high likelihood of preserving renal function. A review of clinical evidence supporting the use of ablative radiotherapy (SABR) in primary, recurrent, and metastatic RCC has been conducted. Given the potential immunogenic effect of the high RT doses, we also explore emerging opportunities to combine SABR with systemic treatments. In addition, we explore future directions and ongoing clinical trials in the evolving landscape of this disease.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39123406</pmid><doi>10.3390/cancers16152678</doi><orcidid>https://orcid.org/0000-0001-7508-1544</orcidid><orcidid>https://orcid.org/0000-0002-2677-5627</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 2072-6694
ispartof	Cancers, 2024-07, Vol.16 (15), p.2678
issn	2072-6694 2072-6694
language	eng
recordid	cdi_proquest_miscellaneous_3091284977
source	NCBI_PubMed Central（免费）; ProQuest - Publicly Available Content Database
subjects	Ablation Cancer therapies Clinical trials Cryotherapy Dialysis Hemodialysis Immunogenicity Invasiveness Kidney cancer Metastases Metastasis Oncology Palliation Patients Radiation therapy Radioresistance Radiosurgery Renal function Surgery Surgical outcomes Toxicity Tumors
title	The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC)
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A55%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Landscape%20of%20Stereotactic%20Ablative%20Radiotherapy%20(SABR)%20for%20Renal%20Cell%20Cancer%20(RCC)&rft.jtitle=Cancers&rft.au=Moreno-Olmedo,%20Elena&rft.date=2024-07-27&rft.volume=16&rft.issue=15&rft.spage=2678&rft.pages=2678-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16152678&rft_dat=%3Cproquest_cross%3E3091284977%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c209t-a41bee70ea2d496bcb9b68d970186165128bad023ccf996f8e409cd3c44188c23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3090883986&rft_id=info:pmid/39123406&rfr_iscdi=true